BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zheng Q, Yang Q, Zhou J, Gu X, Zhou H, Dong X, Zhu H, Chen Z. Immune signature-based hepatocellular carcinoma subtypes may provide novel insights into therapy and prognosis predictions. Cancer Cell Int 2021;21:330. [PMID: 34193146 DOI: 10.1186/s12935-021-02033-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhu Y, Shan D, Guo L, Chen S, Li X. Immune-Related lncRNA Pairs Clinical Prognosis Model Construction for Hepatocellular Carcinoma. IJGM 2022;Volume 15:1919-31. [DOI: 10.2147/ijgm.s343350] [Reference Citation Analysis]
2 Chen H, Wang J, Zeng R, Luo Y, Guo K, Wu H, Yang Q, Jiang R, Sha W, Zhuo Z. Development and Validation of a Novel Mitophagy-Related Gene Prognostic Signature for Hepatocellular Carcinoma Based on Immunoscore Classification of Tumor. J Oncol 2021;2021:5070099. [PMID: 34733329 DOI: 10.1155/2021/5070099] [Reference Citation Analysis]
3 Xue C, Zhao Y, Li G, Li L. Multi-Omic Analyses of the m5C Regulator ALYREF Reveal Its Essential Roles in Hepatocellular Carcinoma. Front Oncol 2021;11:633415. [PMID: 34367948 DOI: 10.3389/fonc.2021.633415] [Reference Citation Analysis]
4 Wang Z, Wen P, Hu B, Cao S, Shi X, Guo W, Zhang S. Dopamine and dopamine receptor D1 as a novel favourable biomarker for hepatocellular carcinoma. Cancer Cell Int 2021;21:586. [PMID: 34717619 DOI: 10.1186/s12935-021-02298-9] [Reference Citation Analysis]